Daniel Faga, AnaptysBio CEO
October 9, 2023 03:00 PM EDT
Deals
R&D

Anap­tys­Bio touts PhI­II win in a rare form of pso­ri­a­sis. But it does­n't plan on keep­ing the drug

Nicole DeFeudis

Editor

Anap­tys­Bio’s an­ti­body for a rare form of pso­ri­a­sis passed a Phase III study, but it’s still get­ting the boot, the com­pa­ny

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

Maze's ALS spin­out Trace Neu­ro­science rais­es $101M for ALS and neu­ro work

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

Up­dat­ed: As­traZeneca, Dai­ichi Sankyo re­place lung can­cer fil­ing for En­her­tu suc­ces­sor

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times